AI in Pharma R&D: Why Digital Discovery Depends on Operating Discipline
Artificial intelligence has moved to the center of pharmaceutical R&D strategy. The promise is compelling: faster target identification, better molecule design, stronger asset scouting, improved trial planning, and more informed portfolio decisions. But for billion-dollar pharmaceutical companies, the decisive question is no longer whether AI has potential. It is whether AI can be converted into repeatable R&D and portfolio performance.
Recent deal activity shows how quickly the market is moving. Reuters reported in June 2026 that Alnylam and Inceptive entered an AI-driven RNA medicine discovery partnership worth up to $2 billion. Reuters also reported that Eli Lilly extended a partnership with Insilico Medicine in a deal valued at up to $2.75 billion. These are not small experiments. They signal that AI-enabled discovery is becoming part of mainstream pharmaceutical strategy.
At the same time, FDA’s 2025 novel drug approvals show that development speed and regulatory discipline remain central. CDER approved 46 novel drugs in 2025, and its annual report notes that 33 of those approvals, or 72%, used one or more expedited programs. AI may help identify and design assets faster, but value is only realized when those assets move through development, regulation, and launch with discipline.
AI will not transform pharma R&D unless it changes decisions, workflows, and portfolio execution.
AI Is Raising Expectations for R&D Throughput
Pharma R&D has long struggled with high cost, long timelines, and low probability of success. AI offers the possibility of improving multiple points in the value chain: target discovery, molecular design, toxicity prediction, competitive intelligence, biomarker strategy, patient stratification, protocol design, and evidence synthesis. But improving isolated steps does not automatically improve portfolio outcomes.
The danger is that AI becomes another layer of tools, pilots, dashboards, and specialized teams that operate outside the core decision system. When that happens, scientific insights may be generated faster, but they do not reliably change prioritization, resource allocation, or development execution. AI value stalls when the operating model is not ready to absorb it.
The CEO-level question is not how many AI pilots are underway. It is whether AI is improving cycle time, decision quality, probability of technical success, asset prioritization, and portfolio return.
Portfolio Governance Must Adapt to Faster Insight
AI can produce more hypotheses, more candidate assets, and more competitive intelligence than traditional processes can easily absorb. Without stronger governance, faster insight can create noise. Leadership teams may face more options but not better decisions. R&D organizations may advance too many assets, overload scarce capabilities, or fail to kill weak programs quickly enough.
Effective AI-enabled R&D requires a portfolio operating model that clarifies where AI informs decisions, what evidence thresholds matter, who owns the decision, and how resource allocation changes as new information emerges. The stage-gate process must become more dynamic without becoming undisciplined.
This is where many organizations will either create value or lose it. AI should help leadership focus resources on the strongest opportunities, not expand the number of parallel efforts beyond what development, regulatory, and commercial teams can execute.
Governance and Adoption Are the Real Scaling Barriers
Many pharmaceutical companies can identify compelling AI use cases. Fewer can scale them across the enterprise in a way that changes how work is done. Scientific teams may trust some models but not others. Legal and compliance teams may need stronger controls. Data teams may struggle with quality, lineage, and access. Business leaders may not know how to translate model outputs into portfolio decisions.
This makes governance and adoption central to the AI value case. Leaders need to define where human review is required, how models are validated, how data is governed, how decisions are documented, and how risk is managed. They also need to redesign workflows so scientists, clinical teams, and portfolio leaders actually use AI in the moments that matter.
The companies that scale AI successfully will not treat adoption as a change-management afterthought. They will build clear operating rules, training, decision templates, feedback loops, and performance metrics that make AI a practical part of R&D execution.
AI Must Improve the Economics of the Portfolio
AI initiatives should ultimately improve the economics of the R&D portfolio. That may mean faster cycle times, stronger asset selection, fewer weak programs advancing too long, better trial design, improved enrollment strategy, or more efficient use of scientific talent. Each use case should be linked to a business outcome that leadership can measure.
Without that discipline, AI can become expensive optionality. Partnerships, platforms, and models may generate excitement but still fail to change the portfolio’s risk-adjusted value. Pharma CEOs need an operating model that makes AI accountable to outcomes, not headlines.
Digital Discovery Must Connect to Development Execution
Discovery is only the first part of value creation. Even a promising AI-generated or AI-prioritized asset must move through preclinical work, CMC planning, regulatory strategy, trial design, site activation, patient enrollment, data management, and commercialization planning. If these handoffs are weak, upstream speed can simply move bottlenecks downstream.
FDA’s use of expedited programs underscores the importance of development readiness. Assets that move faster require stronger evidence planning, clearer regulatory alignment, and more disciplined cross-functional coordination. AI can support these steps, but it cannot substitute for accountable execution across development operations.
The organizations that win will connect AI-enabled discovery to a full development operating system. That means AI outputs must become decisions, decisions must become funded plans, and plans must become governed execution with leading indicators and accountability.
The Brooks International Perspective
From Brooks International’s perspective, AI in pharma R&D is an operating model challenge as much as a technology opportunity. The value is not in the model alone. The value is in how the enterprise uses AI to make better decisions, move faster, allocate resources more effectively, and improve the probability that promising assets reach patients and markets.
Brooks International would focus on the management system around AI-enabled R&D: use-case prioritization, decision rights, portfolio cadence, workflow redesign, evidence thresholds, data governance, cross-functional handoffs, and the connection between R&D insights and commercial or manufacturing implications.
This is especially important because AI can accelerate the wrong work as easily as the right work. If decision processes are unclear, AI may increase activity without improving outcomes. If portfolio governance is weak, teams may chase more assets without sufficient focus. If development execution is not aligned, upstream speed can expose downstream constraints.
The opportunity is significant, but the discipline required is equally important. AI can compress timelines and expand scientific reach, but it can also create false confidence if governance is weak or if teams cannot explain why decisions are being made. Pharma leaders need a system that combines scientific ambition with operational rigor, ensuring that AI-enabled speed does not come at the expense of evidence quality, regulatory readiness, or portfolio focus.
Brooks International’s perspective is that digital discovery depends on operating discipline. The companies that capture AI value will be those that embed it into the way the enterprise makes decisions and manages performance, not those that simply accumulate tools and partnerships.
What Pharmaceutical Leaders Should Be Asking Now
The leadership agenda should focus on whether AI is changing R&D performance, not just expanding activity:
- Which AI use cases are tied to measurable R&D, portfolio, or development outcomes?
- Does the organization have clear decision rights for acting on AI-generated insights?
- Are AI outputs changing asset prioritization, resource allocation, and stop/go decisions?
- Can development, regulatory, CMC, and commercial teams absorb faster discovery without creating downstream bottlenecks?
- Are governance, data quality, validation, and risk controls keeping pace with AI adoption?
- Does leadership have leading indicators that show whether AI is improving cycle time, decision quality, and portfolio value?
These questions matter because AI’s strategic value is not measured by experimentation. It is measured by whether it improves the speed and quality of enterprise decisions.
The Leadership Imperative
AI is changing the expectations placed on pharmaceutical R&D. Investors, boards, and scientific leaders will increasingly expect discovery and development organizations to move faster, learn faster, and allocate capital more intelligently.
For pharmaceutical CEOs, the mandate is to turn AI from a set of promising technologies into a governed operating capability. That means embedding AI into workflows, decision cadence, portfolio management, and execution routines in a way that improves measurable outcomes.
The companies that win will not simply use AI. They will build R&D operating systems that know how to turn AI into performance.
